PILOCARPINE HYDROCHLORIDE TABLETS, USP

国: カナダ

言語: 英語

ソース: Health Canada

有効成分:

PILOCARPINE HYDROCHLORIDE

から入手可能:

STERIMAX INC

ATCコード:

N07AX01

INN（国際名）:

PILOCARPINE

投薬量:

5MG

医薬品形態:

TABLET

構図:

PILOCARPINE HYDROCHLORIDE 5MG

投与経路:

ORAL

パッケージ内のユニット:

100

処方タイプ:

Prescription

治療領域:

PARASYMPATHOMEMETIC (CHOLINERGIC) AGENTS

製品概要:

Active ingredient group (AIG) number: 0107358009; AHFS:

認証ステータス:

APPROVED

承認日:

2013-02-26

製品の特徴

_ _
_Pilocarpine Hydrochloride Tablets, USP Product Monograph _
_Page 1 of 30 _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
Pr
PILOCARPINE HYDROCHLORIDE
TABLETS, USP
5 MG TABLETS
CHOLINOMIMETIC AGENT
SteriMax Inc.
2770 Portland Drive
Oakville, ON L6H 6R4
DATE OF REVISION:
June 23, 2015
Submission Control No: 182910
_Pilocarpine Hydrochloride Tablets, USP Product Monograph _
_ Page 2 of 30_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................ 3
SUMMARY PRODUCT INFORMATION
.......................................................................
3
INDICATIONS AND CLINICAL USE
.............................................................................
3
CONTRAINDICATIONS
..................................................................................................
4
WARNINGS AND PRECAUTIONS
.................................................................................
4
ADVERSE REACTIONS
...................................................................................................
7
DRUG INTERACTIONS
.................................................................................................
12
DOSAGE AND ADMINISTRATION
.............................................................................
12
OVERDOSAGE
...............................................................................................................
13
ACTION AND CLINICAL PHARMACOLOGY
........................................................... 13
STORAGE AND STABILITY
.........................................................................................
17
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................ 17
PART II: SCIENTIFIC INFORMATION
...............................................................................
19
PHARMACEUTICAL INFORMATION
.........................................................................
19
CLINICAL TRIALS
..............................................................................